Michael Barbella, Managing Editor03.25.21
CareSignal is expanding its Deviceless Remote Patient Monitoring (RPM) offering to entities providing (or planning to provide) virtual care.
The company is partnering with Deloitte to offer that firm's healthcare clients its Deviceless RPM, an accessible, condition-specific monitoring and engagement solution that delivers improved clinical visibility and strong financial returns for all value-based populations.
“CareSignal is excited to have the opportunity to serve Deloitte and the organization’s industry-leading healthcare clients nationally,” said Blake Marggraff, CEO and founder of CareSignal. “The fundamental priority for our company is long-term, clinically actionable engagement for the most challenging populations, including those with health literacy and technological limitations. Together, I am confident that CareSignal and Deloitte will positively impact both the patients and the organizations that have the most to gain during the continued transition to digital-first care.”
The COVID-19 pandemic, along with subsequent operational shifts, have forced healthcare delivery away from analog and toward digital. CareSignal Deviceless RPM, with 12 peer-reviewed journal publications, provides care teams with the real-time data necessary to sustain clinically impactful relationships, especially those working with chronic and behavioral health conditions.
Jay Compton, managing director, Deloitte Consulting LLP, and chief technology officer, ConvergeHEALTH by Deloitte, emphasized the timeliness of scalable, clinically actionable remote monitoring: “This offering combines the best of traditional remote patient monitoring and large-scale patient engagement. By leveraging universally available technology, ranging from landline phone calls and text messages to smartphone apps, prior barriers to successful long-term monitoring are eliminated with this offering.”
The Deloitte-CareSignal collaboration is the result of extensive diligence and detailed market analysis.
“The deep clinical evidence and demonstrated real-world financial impact of CareSignal are compelling,” said Bill Fera, M.D., principal, Deloitte Consulting LLP. “As the early majority adopt value-based, patient-centered models of care, a strong, operationally viable technology strategy must include not only population health and virtual care delivery, but also the type of longitudinal remote monitoring CareSignal and Deloitte now provide.”
The company is partnering with Deloitte to offer that firm's healthcare clients its Deviceless RPM, an accessible, condition-specific monitoring and engagement solution that delivers improved clinical visibility and strong financial returns for all value-based populations.
“CareSignal is excited to have the opportunity to serve Deloitte and the organization’s industry-leading healthcare clients nationally,” said Blake Marggraff, CEO and founder of CareSignal. “The fundamental priority for our company is long-term, clinically actionable engagement for the most challenging populations, including those with health literacy and technological limitations. Together, I am confident that CareSignal and Deloitte will positively impact both the patients and the organizations that have the most to gain during the continued transition to digital-first care.”
The COVID-19 pandemic, along with subsequent operational shifts, have forced healthcare delivery away from analog and toward digital. CareSignal Deviceless RPM, with 12 peer-reviewed journal publications, provides care teams with the real-time data necessary to sustain clinically impactful relationships, especially those working with chronic and behavioral health conditions.
Jay Compton, managing director, Deloitte Consulting LLP, and chief technology officer, ConvergeHEALTH by Deloitte, emphasized the timeliness of scalable, clinically actionable remote monitoring: “This offering combines the best of traditional remote patient monitoring and large-scale patient engagement. By leveraging universally available technology, ranging from landline phone calls and text messages to smartphone apps, prior barriers to successful long-term monitoring are eliminated with this offering.”
The Deloitte-CareSignal collaboration is the result of extensive diligence and detailed market analysis.
“The deep clinical evidence and demonstrated real-world financial impact of CareSignal are compelling,” said Bill Fera, M.D., principal, Deloitte Consulting LLP. “As the early majority adopt value-based, patient-centered models of care, a strong, operationally viable technology strategy must include not only population health and virtual care delivery, but also the type of longitudinal remote monitoring CareSignal and Deloitte now provide.”